ChemoCentryx's Avacopan, gets U.S. FDA approval for treating rare autoimmune disease

Highlights

• Avacopan gets approval from US FDA
• This drug is used to treat antineutrophil cytoplasmic antibody associated vasculitides

ChemoCentryx Inc, lead drug for treating a rare, fatal autoimmune disease has been approved by the U.S. health agency. This has caused the shares of the biopharmaceutical company to go up by more than 70%.

The drug is called as Avacopan and....